Allegiance Equity Corporation Update On Recent Developments
Friday, 31 July 2009 12:38 PM
Promissory Note
Allegiance has received $185,000 secured by a Promissory Note dated July 15th, 2009 bearing interest payable at the rate of seven (7%) per annum payable quarterly. The Promissory Note is for a three year term with the principal repayable on July 15, 2012. The proceeds will be applied towards working capital.
Settlement of Lawsuit with Innovative Life Sciences Corporation (“Innovative”)
Innovative, a company in which Allegiance is a minority shareholder, had filed a Statement of Claim in the Ontario Court of Justice against Legacy Research Corporation (“Legacy”) and David Solomon, President of Allegiance, to set aside a License Agreement between Legacy and Innovative. A settlement between all of the parties has been reached with Innovative paying $150,000 to Legacy in exchange for terminating the Licence Agreement.
Sale of Innovative Shares by Allegiance to Legacy
Allegiance had purchased 2,500,000 common shares of Innovative for $10,000 and has now agreed to sell to Legacy 750,000 common shares for $75,000.00. Legacy, a private company, is purchasing the common shares of Innovative for investment purposes. Previously, Allegiance had disposed of 450,000 common shares of Innovative for $45,000 to arms’ length parties. Allegiance now holds 1,300,000 common shares of Innovative.
For more information:
David Solomon, President
Allegiance Equity Corporation
Tel: 416-630 1221
E-mail: [email protected]
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
